Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization - Lincoff, AM; Tcheng, JE; Califf, RM; Bass, T; Popma, JJ; Teirstein, PS; Kleiman, NS; Hattel, LJ; Anderson, HV; Ferguson, JJ; Cabot, CF; Anderson, KM; Berdan, LG; Musco, MH; Weisman, HF; Topol, EJ (Am J Cardiol, 1997)